JLPC(SH:600513) Jin Rong Jie·2025-08-04 05:53Core Viewpoint - On August 4, Lianhuan Pharmaceutical experienced a 9.98% increase in stock price, reaching 20.82 CNY per share, with a trading volume of 1.163 billion CNY and a turnover rate of 21.09%, resulting in a total market capitalization of 5.943 billion CNY [1] Company Overview - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various forms of medications including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Nifedipine. The company boasts a high-end R&D team of nearly 200 members and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025 (January to March), Lianhuan Pharmaceutical reported a revenue of 628 million CNY, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million CNY, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]